US 12,269,817 B2
Compound having KDM5 inhibitory activity and pharmaceutical use thereof
Akito Kakuuchi, Osaka (JP); Shuhei Umemura, Osaka (JP); Masaki Asada, Osaka (JP); Anatoly Ruvinsky, Lexington, MA (US); Yan Zhang, New York, NY (US); Hidenori Takahashi, Lagrangeville, NY (US); Goran Krilov, Long Island City, NY (US); Daigo Inoyama, Ridgewood, NJ (US); Kyle Konze, Brooklyn, NY (US); and Mats Svensson, New York, NY (US)
Assigned to ONO PHARMACEUTICAL CO., LTD., Osaka (JP)
Filed by ONO PHARMACEUTICAL CO., LTD., Osaka (JP)
Filed on May 5, 2023, as Appl. No. 18/144,030.
Application 18/144,030 is a continuation of application No. 17/971,844, filed on Oct. 24, 2022, granted, now 11,691,968.
Application 17/971,844 is a continuation of application No. PCT/CN2021/091843, filed on May 6, 2021.
Claims priority of application No. PCT/CN2020/088925 (WO), filed on May 7, 2020.
Prior Publication US 2023/0271952 A1, Aug. 31, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 413/14 (2006.01)
CPC C07D 413/14 (2013.01) 3 Claims
 
1. A pharmaceutical composition comprising [(1R,5S,6r)-6-(5,5-dimethyl-4,5-dihydro-1,2-oxazol-3-yl)-3-azabicyclo [3.1.0] hex-3-yl] [1-(1-methylcyclopropyl)-1H-imidazol-4-yl] methanone or a salt thereof, and a pharmaceutically acceptable carrier.